How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,679 results for

Indinavir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. The mechanism for differential effect of nelfinavir and indinavir on collagen metabolism in human skin fibroblasts. (Abstract)

The mechanism for differential effect of nelfinavir and indinavir on collagen metabolism in human skin fibroblasts. The mechanism for differential effects of human immune deficiency virus protease inhibitors (HIVPIs), nelfinavir (NEL) and indinavir (IND) on collagen metabolism disturbances was studied in human skin fibroblasts. It has been considered that HIVPIs-dependent deregulation of collagen biosynthesis involves prolidase (an enzyme providing proline for collagen biosynthesis), glutamine

2019 Experimental Dermatology

2. Indinavir and atazanavir; comparison of predicted property by chemoinformatics technique and implication on renal problem in HIV infected patients Full Text available with Trip Pro

Indinavir and atazanavir; comparison of predicted property by chemoinformatics technique and implication on renal problem in HIV infected patients 28197526 2018 11 13 2345-4202 6 1 2017 Journal of nephropharmacology J Nephropharmacol Indinavir and atazanavir; comparison of predicted property by chemoinformatics technique and implication on renal problem in HIV infected patients. 21-22 Joob Beuy B Sanitation 1 Medical Academic Center, Bangkok, Thailand. Wiwanitkit Viroj V Visiting Professor (...) , Hainan Medical University, Haikou, China ; Visiting Professor, Faculty of Medicine, University of Nis, Serbia; adjunct professor, Joseph Ayobabalola University, Nigeria; Honorary Professor, Dr DY Patil Medical University, India. eng Journal Article 2016 01 21 Iran J Nephropharmacol 101679372 2345-4202 Atazanavir Human immunodeficiency virus Indinavir Renal 2016 01 01 2016 01 18 2017 2 16 6 0 2017 2 16 6 0 2017 2 16 6 1 epublish 28197526 PMC5295654 Chem Biol Drug Des. 2013 Apr;81(4):527-36 23279875 J

2016 Journal of nephropharmacology

3. α-7-nicotinic acetylcholine receptor inhibition by indinavir: implications for cognitive dysfunction in treated HIV disease. (Abstract)

α-7-nicotinic acetylcholine receptor inhibition by indinavir: implications for cognitive dysfunction in treated HIV disease. The study set out to determine if the HIV protease inhibitor, indinavir, alters responsiveness of α7-nicotinic acetylcholine receptors to acetylcholine.Treatment with HAART has dramatically reduced development of HIV-associated dementia and more severe forms of cognitive impairment. However, many individuals continue to experience cognitive decline of uncertain cause (...) was tested using a ScreenPatch IonWorks Barracuda-based assay in a mammalian cell model.At low concentrations (0.0003-10 μmol/l) indinavir acts as a positive allosteric modulator (EC50 = 0.021 μmol/l), whereas at concentrations greater than 10 μmol/l (30-100 μmol/l) indinavir acts as an inhibitor of the α7-nicotinic acetylcholine receptor.At concentrations greater than 10 μmol/l indinavir reduces synaptic transmission in the acetylcholine neurotransmitter system, which could possibly contribute

2017 AIDS

4. Indinavir

Indinavir Indinavir Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Indinavir Indinavir Aka: Indinavir , Crixivan From Related (...) , インジナビル Spanish indinavir (producto) , indinavir (sustancia) , indinavir , Indinavir French Indinavir German Indinavir Italian Indinavir Portuguese Indinavir Derived from the NIH UMLS ( ) Ontology: Crixivan (C0701105) Concepts Pharmacologic Substance ( T121 ) , Organic Chemical ( T109 ) MSH English indinavir sulfate (Crixivan) , crixivan , Crixivan Derived from the NIH UMLS ( ) Related Topics in Pharmacology About FPnotebook.com is a rapid access, point-of-care medical reference for primary care

2018 FP Notebook

5. A rodent model of HIV protease inhibitor indinavir induced peripheral neuropathy. Full Text available with Trip Pro

A rodent model of HIV protease inhibitor indinavir induced peripheral neuropathy. HIV-associated sensory neuropathy (HIV-SN) is the most frequent manifestation of HIV disease. It often presents with significant neuropathic pain and is associated with previous exposure to neurotoxic nucleoside reverse transcriptase inhibitors. However, HIV-SN prevalence remains high even in resource-rich settings where these drugs are no longer used. Previous evidence suggests that exposure to indinavir (...) , a protease inhibitor commonly used in antiretroviral therapy, may link to elevated HIV-SN risk. Here, we investigated whether indinavir treatment was associated with the development of a "dying back" axonal neuropathy and changes in pain-relevant limb withdrawal and thigmotactic behaviours. After 2 intravenous injections of indinavir (50 mg/kg, 4 days apart), adult rats developed hind paw mechanical hypersensitivity, which peaked around 2 weeks post first injection (44% reduction from baseline

2016 Pain

6. Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. (Abstract)

Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. To assess the effects of venlafaxine extended-release (XR) capsules and desvenlafaxine extended-release (XR) tablets upon indinavir pharmacokinetic properties when co-administrated to healthy volunteers.This was an open-label, two-period, fixed-dose study conducted at the clinical research unit located on a university campus. Twenty-four healthy volunteers (...) enrolled in the study (mean age 28.3 ± 8.0 years). Each subject received a single dose of indinavir 800 mg on day 1. Subsequently, subjects were then randomly assigned to either the venlafaxine XR group (N = 12) or the desvenlafaxine XR group (N = 12). Starting on day 2, venlafaxine XR was dosed at 37.5 mg/day for 4 days and increased to 75 mg/day for 6 days. Desvenlafaxine XR was dosed at 50 mg/day for 10 days. On day 12, indivanvir 800 mg was co-administered to both the venlafaxine XR

2012 European journal of clinical pharmacology Controlled trial quality: uncertain

7. Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398 Full Text available with Trip Pro

Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398 The present population pharmacokinetic (PK) and pharmacodynamic (PD) study modeled the effects of covariates including drug adherence and the coadministration of protease inhibitors (PIs) on the pharmacokinetics of efavirenz (EFV) and the relationship between EFV exposure and virological failure in patients who failed initial PI treatment in Adult AIDS Clinical (...) Trial Group (AACTG) study 398. We also report on the population PKs of the PIs nelfinavir (NFV) and indinavir (IDV). AACTG study 398 patients received EFV, amprenavir, adefovir dipivoxil, and abacavir and were randomized to take, in addition, one of the following: NFV, IDV, saquinavir (SQV), or placebo. The PK databases consisted of 531 EFV concentrations (139 patients), 219 NFV concentrations (75 patients), and 66 IDV concentrations (11 patients). Time to virological failure was ascertained for all

2013 Antimicrobial Agents and Chemotherapy Controlled trial quality: uncertain

8. Indinavir

Indinavir Indinavir Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Indinavir Indinavir Aka: Indinavir , Crixivan From Related (...) , インジナビル Spanish indinavir (producto) , indinavir (sustancia) , indinavir , Indinavir French Indinavir German Indinavir Italian Indinavir Portuguese Indinavir Derived from the NIH UMLS ( ) Ontology: Crixivan (C0701105) Concepts Pharmacologic Substance ( T121 ) , Organic Chemical ( T109 ) MSH English indinavir sulfate (Crixivan) , crixivan , Crixivan Derived from the NIH UMLS ( ) Related Topics in Pharmacology About FPnotebook.com is a rapid access, point-of-care medical reference for primary care

2015 FP Notebook

9. Enhanced anti-HIV efficacy of Indinavir after inclusion in CD4 targeted lipid nanoparticles Full Text available with Trip Pro

Enhanced anti-HIV efficacy of Indinavir after inclusion in CD4 targeted lipid nanoparticles Combination drug therapy has reduced plasma HIV to undetectable levels; however, drug-sensitive virus persists in patients' lymphoid tissue. We have reported significant lymphoid tissue drug localization with indinavir-associated lipid nanoparticles (LNPs). Our current objective is to evaluate whether additional enhancement is achievable by targeting these particles to CD4-HIV host cells.We characterized (...) 2 peptide-coated (CD4-BP2 and CD4-BP4) drug-associated LNPs and demonstrated CD4-cell specificity. Drug-associated LNPs expressing polyethyleneglycol were exposed on HIV-2-infected cells under dynamic conditions that emulated lymph node physiology for 15, 30, and 60 minutes at concentrations from 0 to 25 μM and evaluated for antiviral activity and cell-associated drug concentrations. The specificity of CD4-mediated enhancement of indinavir LNPs antiviral activity was evaluated by blocking

2012 Journal of acquired immune deficiency syndromes (1999)

10. Lack of Indinavir Effects on Methadone Disposition Despite Inhibition of Hepatic and Intestinal Cytochrome P4503A (CYP3A). Full Text available with Trip Pro

Lack of Indinavir Effects on Methadone Disposition Despite Inhibition of Hepatic and Intestinal Cytochrome P4503A (CYP3A). Methadone disposition and pharmacodynamics are highly susceptible to interactions with antiretroviral drugs. Methadone clearance and drug interactions have been attributed to cytochrome P4503A4 (CYP3A4), but actual mechanisms are unknown. Drug interactions can be clinically and mechanistically informative. This investigation assessed effects of the protease inhibitor (...) indinavir on methadone pharmacokinetics and pharmacodynamics, hepatic and intestinal CYP3A4/5 activity (using alfentanil), and intestinal transporter activity (using fexofenadine).Twelve healthy volunteers underwent a sequential crossover. On three consecutive days they received oral alfentanil plus fexofenadine, intravenous alfentanil, and intravenous plus oral (deuterium-labeled) methadone. This was repeated after 2 weeks of indinavir. Plasma and urine analytes were measured by mass spectrometry

2012 Anesthesiology

11. Development of Indinavir Submicron Lipid Emulsions Loaded with Lipoamino Acids—In Vivo Pharmacokinetics and Brain-Specific Delivery Full Text available with Trip Pro

Development of Indinavir Submicron Lipid Emulsions Loaded with Lipoamino Acids—In Vivo Pharmacokinetics and Brain-Specific Delivery The aim of our present work was to develop indinavir O/W submicron lipid emulsions (SLEs) loaded with lipoamino acids for specific delivery to brain. Tetradecyl aspartic acid (A) and decyl glutamic acid (G) loaded stable SLEs of indinavir having a mean size range of 210-220 nm and average zeta potential of -23.54±1.2 mV were developed using homogenization (...) and ultrasonication. The cumulative % drug release from different SLEs varied in between 26% and 85%. The formulations, SLE, SLE-A3, and SLE-G3 were stable to the centrifugal stress, dilution stress, and storage at RT. The total drug content and entrapment efficiency were determined by HPLC method. During pharmacokinetic studies in male Wistar rats there was no significant difference in the serum levels of indinavir for SLE, SLE-A3 and SLE-G3 formulations at all time points. In tissue distribution studies

2011 AAPS PharmSciTech

12. Covid-19: Effectiveness and safety of antiviral or antibody treatments for coronavirus

• protease inhibitors o boceprevir o telaprevir o lopinavir o ritonavir o darunavir/cobicistat (Prezcobix) o indinavir (Crixivan) o saquinavir (Invirase) • integrase inhibitors o raltegravir o elvitegravir o dolutegravir • entry (fusion) inhibitors o maraviroc o celsentri • nucleoside reverse transcriptase inhibitors o abacavir o ziagen o emtricitabine o emtriva o lamivudine o epivir o tenofovir o viread o zidovudine o azidothymidine o retrovir • nonnucleoside reverse transcriptase inhibitors o

2020 Covid-19 Ad hoc papers

13. Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V

medication considered necessary for the patient’s wellbeing and not interacting with the study medication could be administered at the physician’s discretion (e.g. antiemetics) ? bisphosphonates or denosumab were allowed as long as their intake started at least 5 days prior to randomization Non-permitted concomitant treatment ? further cancer treatments (including investigational drugs) ? CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

14. Acute Kidney Injury (AKI)

sulphonamides, acyclovir, triamterene, indinavir and phosphate-rich laxatives. The role of urinary electrolyte measurement in determining the aetiology of an episode of AKI remains unclear. In pre-renal disease (i.e. acute kidney impairment rather than injury) there is increased urinary sodium reabsorption. This should be reflected by a low urine sodium concentration and a low fractional excretion of sodium (FENa, where FENa = (urine Na + x plasma Cr)/(plasma Na + x urine Cr)). However, results should

2019 Renal Association

15. The efficacy of post-exposure prophylaxis (PEP) for HIV

) Tenofovir disoproxil fumarate (TDF) Zidovudine (ZDV*; AZT) Non-nucleoside reverse tran­scriptase inhibitors (NNRTIs) Efavirenz (EFV) Nevirapine (NVP) Rilpivirine (RPV) Protease inhibitors (PIs) Atazanavir (ATV) Darunavir (DRV) Indinavir (IDV) Lopinavir (LPV) Nelfinavir (NFV) Entry inhibitors (EIs) Maraviroc (MVC) Integrase strand transfer inhibi­tors (INSTIs) Dolutegravir (DTG) Elvitegravir (EVG) Raltegravir (RAL) Booster drugs Cobicistat (c) Ritonavir (r) *this review uses ZDV as the acronym

2019 Ontario HIV Treatment Network

16. Should Protease Inhibitors be Used for COVID-19?

, RCT ASC09 with ritonavir Lopinavir/ritonavir May 2020 NCT04315948 11 MC, OL, RCT ? Remdesivir ? lopinavir/ritonavir ? lopinavir/ritonavir with interferon ß-1a Standard of care March 2023 † The literature search covered antiretroviral HIV-1 protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir); and hepatitis C virus NS3/4A protease inhibitors (asunaprevir, boceprevir, grazoprevir, glecaprevir, paritaprevir

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

17. Should Protease Inhibitors be Used for COVID-19?

2020 NCT04315948 11 MC, OL, RCT ? Remdesivir ? Lopinavir/ritonavir ? Lopinavir/ritonavir with interferon ß-1a Standard of care March 2023 † The literature search covered antiretroviral HIV-1 protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir); and hepatitis C virus NS3/4A protease inhibitors (asunaprevir, boceprevir, grazoprevir, glecaprevir, paritaprevir, simeprevir, telaprevir and danoprevir). MOH-ACE COVID

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

18. Atezolizumab (non-small cell lung cancer) ? Benefit assessment according to §35a Social Code Book V

, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, or voriconazole) Atezolizumab: ? active immunization with live vaccines during the study ? herbal drugs ? immunomodulatory drugs (until 10 weeks after end of study) and immunosuppressants ? RANKL inhibitor (denosumab) (continued) Extract of dossier assessment A17-50 Version 1.0 Atezolizumab (non-small cell lung cancer) 27 December 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - 15 - Table 7 (...) , day 14 radiotherapy for alleviation of pain ? bisphosphonates for prevention of skeletal-related events Docetaxel: ? granulocyte-stimulating medications ? antiemetics, antiallergics if approved by the investigator Atezolizumab: ? = cycle 2 systemic corticosteroids, TNFa inhibitors; epinephrine, antihistamines for the treatment of AEs Non-permitted concomitant treatment: Docetaxel: ? CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

19. Treatment algorithm for Cancer-associated Thrombosis (CAT)

agents Vinblastine ? ? ? Anti-mycotic agents Azithromycin ? ? ? Clarithromycin ? ? ? Erythromycin ? ? ? Itroconazole ? ? ? Ketoconazole ? ? ? Posaconazole — ? ? Voriconazole — ? ? Anthracyclines Doxorubicin ? ? ? Hormonal agents Tamoxifen ? ? ? Immune-modulating agents Cyclosporine ? ? ? Dexamethasone ? ? ? Tacrolimus ? ? ? Protease inhibitors Indinavir ? ? ? Nelfinavir ? ? ? Ritonavir ? ? ? Saquinavir ? ? ? Tyrosine kinase inhibitors Imatinib — ? ? Lapatinib ? ? ? Nilotinib ? ? ? Sunitinib

2018 Thrombosis Interest Group of Canada

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>